Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


26.06.2017

3 Am J Epidemiol
1 Am J Pathol
1 Am J Surg
1 Ann Oncol
1 Ann Surg Oncol
3 BMC Cancer
3 Br J Cancer
1 Breast Cancer
4 Breast Cancer Res
12 Breast Cancer Res Treat
5 Cancer
1 Cancer Cell
1 Cancer Res
1 Carcinogenesis
4 Clin Breast Cancer
1 Clin Cancer Res
2 Eur J Cancer
1 Histopathology
3 J Biol Chem
1 J Clin Oncol
1 J Nucl Med
1 JAMA
1 Lancet
3 Lancet Oncol
1 Mod Pathol
1 N Engl J Med
1 Nat Rev Clin Oncol
1 PLoS Genet
4 PLoS One
1 Proc Natl Acad Sci U S A
1 Radiology
2 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Epidemiol

  1. TOBIAS DK, Akinkuolie AO, Chandler PD, Lawler PR, et al
    Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study.
    Am J Epidemiol. 2017 Jun 21. doi: 10.1093.
    PubMed     Text format     Abstract available

  2. MULLOOLY M, Khodr ZG, Dallal CM, Nyante SJ, et al
    Epidemiologic risk factors for in situ and invasive breast cancer among postmenopausal women in the NIH-AARP Diet and Health Study.
    Am J Epidemiol. 2017 Jun 16. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. ANDERSSON TM, Crowther MJ, Czene K, Hall P, et al
    Mammographic density reduction as a prognostic marker for postmenopausal breast cancer; results using a joint longitudinal-survival modelling approach.
    Am J Epidemiol. 2017 Jun 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    Am J Pathol

  4. DOEBAR SC, Sieuwerts AM, de Weerd V, Stoop H, et al
    Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer.
    Am J Pathol. 2017;187:1648-1655.
    PubMed     Text format     Abstract available


    Am J Surg

  5. EL HAGE CHEHADE H, Wazir U, Mokbel K, Kasem A, et al
    Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature.
    Am J Surg. 2017 Jun 3. pii: S0002-9610(17)30531.
    PubMed     Text format     Abstract available


    Ann Oncol

  6. BLACKWELL K, Gascon P, Jones CM, Nixon A, et al
    Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Ann Oncol. 2017 Jun 16. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  7. PARK MH, Kwon HJ, Kim JR, Lee B, et al
    Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.
    Ann Surg Oncol. 2017 Jun 20. doi: 10.1245/s10434-017-5907.
    PubMed     Text format     Abstract available


    BMC Cancer

  8. GRINDEDAL EM, Heramb C, Karsrud I, Ariansen SL, et al
    Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
    BMC Cancer. 2017;17:438.
    PubMed     Text format     Abstract available

  9. JACQUINOT Q, Meneveau N, Chatot M, Bonnetain F, et al
    A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    BMC Cancer. 2017;17:425.
    PubMed     Text format     Abstract available

  10. OZAKI A, Nomura S, Leppold C, Tsubokura M, et al
    Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study.
    BMC Cancer. 2017;17:423.
    PubMed     Text format     Abstract available


    Br J Cancer

  11. MAVROUDIS D, Saloustros E, Boukovinas I, Papakotoulas P, et al
    Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  12. MOSKOWITZ CS, Chou JF, Sklar CA, Barnea D, et al
    Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  13. LEVASSEUR N, Chia SK
    Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    PubMed     Text format    


    Breast Cancer

  14. NAKAI K, Xia W, Liao HW, Saito M, et al
    The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Breast Cancer. 2017 Jun 22. doi: 10.1007/s12282-017-0790.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  15. SAKURAI M, Miki Y, Takagi K, Suzuki T, et al
    Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment.
    Breast Cancer Res. 2017;19:70.
    PubMed     Text format     Abstract available

  16. WANG J, Song C, Tang H, Zhang C, et al
    miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Breast Cancer Res. 2017;19:72.
    PubMed     Text format     Abstract available

  17. PRABHAKARAN S, Rizk VT, Ma Z, Cheng CH, et al
    Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes.
    Breast Cancer Res. 2017;19:71.
    PubMed     Text format     Abstract available

  18. ZHANG G, Zhang W, Li B, Stringer-Reasor E, et al
    MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer.
    Breast Cancer Res. 2017;19:73.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  19. CINTOLO-GONZALEZ JA, Braun D, Blackford AL, Mazzola E, et al
    Erratum to: Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
    Breast Cancer Res Treat. 2017 Jun 21. doi: 10.1007/s10549-017-4349.
    PubMed     Text format    

  20. PARTRIDGE AH, Sepucha K, O'Neill A, Miller KD, et al
    Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
    Breast Cancer Res Treat. 2017 Jun 23. doi: 10.1007/s10549-017-4338.
    PubMed     Text format     Abstract available

  21. HERTZ DL, Speth KA, Kidwell KM, Gersch CL, et al
    Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4346.
    PubMed     Text format     Abstract available

  22. ELEBRO K, Bendahl PO, Jernstrom H, Borgquist S, et al
    Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4343.
    PubMed     Text format     Abstract available

  23. THISTLE JE, Hellberg Y, Mortensen K, Hamilton-Dutoit S, et al
    The effect of 14-3-3zeta expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4289.
    PubMed     Text format     Abstract available

  24. ARTHUR R, Wang Y, Ye K, Glass AG, et al
    Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4347.
    PubMed     Text format     Abstract available

  25. ASKOXYLAKIS V, Kodack DP, Ferraro GB, Jain RK, et al
    Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?
    Breast Cancer Res Treat. 2017 Jun 22. doi: 10.1007/s10549-017-4351.
    PubMed     Text format    

  26. TAN X, Camacho TF, LeBaron VT, Blackhall LJ, et al
    Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
    Breast Cancer Res Treat. 2017 Jun 21. doi: 10.1007/s10549-017-4348.
    PubMed     Text format     Abstract available

  27. CLARK BL, Murphy MA, Kamdem LK
    COX2 induction: a mechanism of endocrine breast cancer resistance?
    Breast Cancer Res Treat. 2017 Jun 21. doi: 10.1007/s10549-017-4284.
    PubMed     Text format     Abstract available

  28. GOLDSTEIN LJ, Zhao F, Wang M, Swaby RF, et al
    A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Gro
    Breast Cancer Res Treat. 2017 Jun 16. doi: 10.1007/s10549-017-4310.
    PubMed     Text format     Abstract available

  29. YAGHJYAN L, Tamimi RM, Bertrand KA, Scott CG, et al
    Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes.
    Breast Cancer Res Treat. 2017 Jun 17. doi: 10.1007/s10549-017-4341.
    PubMed     Text format     Abstract available

  30. LIEDE A, Mansfield CA, Metcalfe KA, Price MA, et al
    Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.
    Breast Cancer Res Treat. 2017 Jun 17. doi: 10.1007/s10549-017-4332.
    PubMed     Text format     Abstract available


    Cancer

  31. ZHANG FF, John EM
    Reply to Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry-methodological issues.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30853.
    PubMed     Text format    

  32. AYUBI E, Safiri S
    Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry-methodological issues.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30852.
    PubMed     Text format    

  33. ABRAHAMS HJG, Gielissen MFM, Donders RRT, Goedendorp MM, et al
    The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30815.
    PubMed     Text format     Abstract available


  34. Perkins P, Cooksley CD and Cox JD. Breast cancer: Is ethnicity an independent prognostic factor for survival? Cancer. 1996;78:1241-1247.
    Cancer. 2017;123:2579.
    PubMed     Text format    

  35. WALLNER LP, Li Y, McLeod MC, Hamilton AS, et al
    Decision-support networks of women newly diagnosed with breast cancer.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30848.
    PubMed     Text format     Abstract available


    Cancer Cell

  36. HYDBRING P, Wang Y, Fassl A, Li X, et al
    Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.
    Cancer Cell. 2017;31:576-590.
    PubMed     Text format     Abstract available


    Cancer Res

  37. HUMPHRIES B, Wang Z, Li Y, Jhan JR, et al
    ARHGAP18 downregulation by miR-200b suppresses metastasis of triple negative breast cancer by enhancing activation of RhoA.
    Cancer Res. 2017 Jun 15. pii: canres.3141.2016.
    PubMed     Text format     Abstract available


    Carcinogenesis

  38. SINGH DK, Gholamalamdari O, Jadaliha M, Ling Li X, et al
    PSIP1/p75 promotes tumorigenicity in breast cancer cells by promoting the transcription of cell cycle genes.
    Carcinogenesis. 2017 Jun 17. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  39. HUSSEIN MM, Gaafar RM, Abdel-Warith AM, Ahmed WA, et al
    Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience.
    Clin Breast Cancer. 2017 May 8. pii: S1526-8209(17)30007.
    PubMed     Text format     Abstract available

  40. YU E, Huang D, Leonard K, Dipetrillo T, et al
    Analysis of Outcomes Using Hypofractionated Tumor Bed Boost Combined With Hypofractionated Whole Breast Irradiation for Early-stage Breast Cancer.
    Clin Breast Cancer. 2017 May 25. pii: S1526-8209(17)30115.
    PubMed     Text format     Abstract available

  41. SHAKER OG, Helmy HS
    Circulating Bone-related Markers and YKL-40 Versus HER2 and TOPO2a in Bone Metastatic and Nonmetastatic Breast Cancer: Diagnostic Implications.
    Clin Breast Cancer. 2017 Jun 7. pii: S1526-8209(17)30150.
    PubMed     Text format     Abstract available

  42. LOURENCO AP, Benson KL, Henderson MC, Silver M, et al
    A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years.
    Clin Breast Cancer. 2017 May 23. pii: S1526-8209(16)30412.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  43. KENNY T, Schmidt H, Adelson K, Hoshida Y, et al
    Patient-derived interstitial fluids and predisposition to aggressive sporadic breast cancer through collagen remodeling and inactivation of p53.
    Clin Cancer Res. 2017 Jun 19. pii: clincanres.0342.2017.
    PubMed     Text format     Abstract available


    Eur J Cancer

  44. GLIGOROV J, Ataseven B, Verrill M, De Laurentiis M, et al
    Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
    Eur J Cancer. 2017 Jun 15. pii: S0959-8049(17)30961.
    PubMed     Text format     Abstract available

  45. PIVOT X, Fumoleau P, Pierga JY, Delaloge S, et al
    Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
    Eur J Cancer. 2017;81:151-160.
    PubMed     Text format     Abstract available


    Histopathology

  46. RAKHA EA, Ahmed MA, Aleskandarany MA, Hodi Z, et al
    Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme.
    Histopathology. 2017;70:632-642.
    PubMed     Text format     Abstract available


    J Biol Chem

  47. JEONG J, VanHouten JN, Kim W, Dann P, et al
    The scaffolding protein NHERF1 regulates the stability and activity of the tyrosine kinase HER2.
    J Biol Chem. 2017;292:6555-6568.
    PubMed     Text format     Abstract available

  48. TAN S, Ding K, Chong QY, Zhao J, et al
    Decreased miR26a/b and increased HuR expression post-transcriptionally upregulates ERBB2 to mediate acquired tamoxifen resistance in ER+ breast cancer cells.
    J Biol Chem. 2017 Jun 21. pii: jbc.M117.780973. doi: 10.1074/jbc.M117.780973.
    PubMed     Text format     Abstract available

  49. MAJKOWSKA I, Shitomi Y, Ito N, Gray NS, et al
    Discoidin domain receptor 2 mediates collagen-induced activation of membrane-type 1 matrix metalloproteinase in human fibroblasts.
    J Biol Chem. 2017;292:6633-6643.
    PubMed     Text format     Abstract available


    J Clin Oncol

  50. STOLLEY M, Sheean P, Gerber B, Arroyo C, et al
    Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors.
    J Clin Oncol. 2017 Jun 19:JCO2016719856. doi: 10.1200/JCO.2016.71.9856.
    PubMed     Text format     Abstract available


    J Nucl Med

  51. MORTIMER JE, Bading JR, Park JM, Frankel PH, et al
    Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.
    J Nucl Med. 2017 Jun 21. pii: jnumed.117.193888. doi: 10.2967/jnumed.117.193888.
    PubMed     Text format     Abstract available


    JAMA

  52. KUCHENBAECKER KB, Hopper JL, Barnes DR, Phillips KA, et al
    Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
    JAMA. 2017;317:2402-2416.
    PubMed     Text format     Abstract available


    Lancet

  53. THE LANCET
    Breast cancer targeted therapy: successes and challenges.
    Lancet. 2017;389:2350.
    PubMed     Text format    


    Lancet Oncol

  54. DIKMANS RE, Negenborn VL, Bouman MB, Winters HA, et al
    Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial.
    Lancet Oncol. 2017;18:251-258.
    PubMed     Text format     Abstract available

  55. DAS M
    Adjuvant pertuzumab improves early breast cancer outcomes.
    Lancet Oncol. 2017 Jun 15. pii: S1470-2045(17)30481.
    PubMed     Text format    

  56. LUEN SJ, Salgado R, Fox S, Savas P, et al
    Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Lancet Oncol. 2017;18:52-62.
    PubMed     Text format     Abstract available


    Mod Pathol

  57. BUISSERET L, Desmedt C, Garaud S, Fornili M, et al
    Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.
    Mod Pathol. 2017 Jun 16. doi: 10.1038/modpathol.2017.
    PubMed     Text format     Abstract available


    N Engl J Med

  58. SCHWARTZ RS, Erban JK
    Timing of Metastasis in Breast Cancer.
    N Engl J Med. 2017;376:2486-2488.
    PubMed     Text format    


    Nat Rev Clin Oncol

  59. ROMERO D
    Breast cancer: Olaparib improves PFS.
    Nat Rev Clin Oncol. 2017 Jun 20. doi: 10.1038/nrclinonc.2017.
    PubMed     Text format    


    PLoS Genet

  60. KAWAZU M, Kojima S, Ueno T, Totoki Y, et al
    Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.
    PLoS Genet. 2017;13:e1006853.
    PubMed     Text format     Abstract available


    PLoS One

  61. KIM HS, Tian L, Kim H, Moon WK, et al
    Investigation of discriminant metabolites in tamoxifen-resistant and choline kinase-alpha-downregulated breast cancer cells using 1H-nuclear magnetic resonance spectroscopy.
    PLoS One. 2017;12:e0179773.
    PubMed     Text format     Abstract available

  62. BUEHRING GC, Shen H, Schwartz DA, Lawson JS, et al
    Bovine leukemia virus linked to breast cancer in Australian women and identified before breast cancer development.
    PLoS One. 2017;12:e0179367.
    PubMed     Text format     Abstract available

  63. LIU JC, Zacksenhouse M, Eisen A, Nofech-Mozes S, et al
    Identification of cell proliferation, immune response and cell migration as critical pathways in a prognostic signature for HER2+:ERalpha- breast cancer.
    PLoS One. 2017;12:e0179223.
    PubMed     Text format     Abstract available

  64. NAZIROGLU M, Cig B, Blum W, Vizler C, et al
    Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels.
    PLoS One. 2017;12:e0179950.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  65. CASCIELLO F, Al-Ejeh F, Kelly G, Brennan DJ, et al
    G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis.
    Proc Natl Acad Sci U S A. 2017 Jun 19. pii: 201618706.
    PubMed     Text format     Abstract available


    Radiology

  66. CONANT EF, Keller BM, Pantalone L, Gastounioti A, et al
    Agreement between Breast Percentage Density Estimations from Standard-Dose versus Synthetic Digital Mammograms: Results from a Large Screening Cohort Using Automated Measures.
    Radiology. 2017;283:673-680.
    PubMed     Text format     Abstract available


    Radiother Oncol

  67. DUANE F, Aznar MC, Bartlett F, Cutter DJ, et al
    A cardiac contouring atlas for radiotherapy.
    Radiother Oncol. 2017;122:416-422.
    PubMed     Text format     Abstract available

  68. LIPPS DB, Sachdev S, Strauss JB
    Quantifying radiation dose delivered to individual shoulder muscles during breast radiotherapy.
    Radiother Oncol. 2017;122:431-436.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: